

References

1. **Samantha Kubaska , Dushyan TV , Sahan I , Sanjay Saint Peter . Hahn Elkan Haipern (2001) :** Dual Contrast Enhanced magnetic Resonance Imaging of the liver with super paramagnetic Iron Oxide Followed by gadolinium for Lesion Detection and characterization .56: 410 – 415 .
2. **L. J. King , G . J .C Burkill , E . D Scurr , P.Vavianos, I.Murray. Lyons , J .C Healy(2002) :** MNDPDP enhanced Magnetic Resonance Imaging of Focal liver lesion clinical radiology 57:1047 – 1057 .
3. **Word J , Naik Ks , Guthrie JA , Wilson D and Robinson PJ (1999) :** Hepatic lesion detection : comparison of MR imaging after the administration of super paramagnetic iron oxide with dual phase CT by using alternative . free response receiver operating characteristic analysis , Radiology , 210 (2) : 459- 66.
4. **Soyer p Gueye C , Somveille e , et al . (1995) :** MR diagnosis of hepatic metastasis form neuroendocrine tumors versus haemangiomas : Relative merits of dynamic gadolinium chelate-enhanced gradient recalled echo and unenhanced spin echoimages . A.JR Am J Roentgenol 165 : 1407
5. **Vilgerian V , silbermann O , Benhamou J.P , et al (1993):** MR imaging in intracystic haemorrhage of simple hepatic cysts , Abdomen imaging 18:164 .
6. **Semelka RC, Khoenot OP, Kroeker MA et al . (1992) :** Focal liver disease Comparison of dynamic contrast enhanced CT and T2 weighted Fat suppressed , Flash , and dynamic gadolinium - enhanced MR imaging at 1.5 T. Radiology . 184 , 687- 694 .
7. **Parks.R-W- and oniscu G.G.** Benign Condition of the liver – surgrey 2006, 25 (1) 22 – 27 .
8. **Gibbs J.F, Litwin A.M, and Kahlenberg M.S.** Contemporary management of benign liver tumors. Surg Clin N Am 84 (2004) 463-480.
9. **Prabhu V.R, and Burt D.A.** Pathology of liver tumors, Surgery (2006), 1- 6.
10. **Crawford J.M.** Liver and Biliary Tract. In: Robbins and Cotran eds. Pathologic Basis of Disease, 7th ed., Kumar V, Abbas A and Fausto N. eds. Saunders 2005: 877- 939
11. **Kakar S, and Burgart L.J.** Tumours of the biliary system. Current Diagnostic Pathology (2005) 11,34-43.
12. **Anthony PP.** Tumors and tumor-like lesions of the liver and biliary tract: etiology, epidemiology and pathology. In: RNM MacSween, AD Burt,BC Portmann, et al ed. Pathology of the Liver. 4th Ed. Churchill, Livingstone 2002: 711-776.
13. **John G.C., Sergio H., Hohn A.B.** Hepatobiliary cystadenoma: A case report and a review of the Literature, Current Surgery Vol. 63(4), 2006: 286-289.
14. **Linehan DC, Jarnagin WR. and Blumgart LH.** Benign Tumors and

- Pseudotumors of the biliary tract. In: Surgery of the liver, Biliary Tract and Pancreas 4th ed. Blumgart LH (ed). Philadelphia Saunders 2007; pp. 802-828.
15. **Saegusa, T, Ito, K, Oba, N, et al**, Enlargement of multiple cavernous hemangioma of the liver in association with pregnancy, Intern Med 1995;34:207.
 16. **Winkfield, B, Vuillemin, E, Rousselet, MC, et al** Progression of a hepatic hemangioma under progestins. Gastroenterol Clin Biol 2001; 25: 108.
 17. **Farges O, Daradkeh S, Bismuth H**. Cavernous hemangiomas of the liver: Are there any indications for resection? World J Surg 1995; 19:19.
 18. **Toshikuni, N, Kawaguchi, K, Miki, H, et al**. Focal nodular hyperplasia coexistent with hemangioma and multiple cysts of the liver. J Gastroenterol 2001; 36:206.
 19. **Moon, WS, Yu, HC, Lee, JM, Kang, MJ**. Diffuse hepatic hemangiomatosis in an adult. J Korean Med Sci 2000; 15:471.
 20. **Lehmann, FS, Beglinger, C, Schnabel, K, et al**, progressive development of diffuse liver hemangiomatosis. J Hepatol 1999; 30:951.
 21. **Haitjema, T, Westermann, CJ, Overtom, TT, et al**. Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease): New insights in pathogenesis, complications, and treatment, Arch Intern Med 1996; 156:714.
 22. **Glinkova, V, Shevah, O, Boaz, M, et al**. Hepatic haemangiomas: possible association with female sex hormones. Gut 2004; 53:1352.
 23. **Chamberlain R.S**. Benign liver tumors. In: Hepatobiliary Surgery. Chamberlain RS and Blumgart LH (eds) Vademecum. Landes Bioscience 2004; PP. 80-100.
 24. **Selby DM, Stocker JT, Wacławski Ma et al**, Infantile Hemangioendothelioma of the liver, Hepatology 1994;20:39-45.
 25. **Nazir Z, and Pervez S**. Malignant vascular tumors of liver in neonates, Journal of Pediatric Surgery (2006) 41, E49-E51.
 26. **Klein WM, Molmenti EP, Colombani PM, et al** Primary Liver Carcinoma Arising in People Younger Than 30 Years. Am J Clin Pathol 2005; 124:512-518.
 27. **Levy A.D**. Hepatic Imaging And Intervention. Clinics in Liver Disease 2002, Vol. 6,1:147-162.
 28. **Heimberger JR, Ros PR, Medgo PJ, et al** Pediatric liver neoplasms: a radiology - pathological correlation. Eur Radiol 1999; 9: 1339-1347.
 29. **Belghiti j, Vilgrain V, and Paradis V**. Benign Liver Tumors. In: Surgery of the Liver, Biliary Tract and Pancreas 4th ed. Blumgart LH (ed) Philadelphia Saunders, 2007; pp. 1131-1151
 30. **Wilson J.F**. Liver Cancer on the Rise. Annals of Internal Medicine 2005; 142, 12: 1029- 1032
 31. **Lang B.H., Poon R.T., Fan S.T. and Wong J**. Outcomes of patients with hepatocellular carcinoma presenting with variceal bleeding, Am. J

- Gastroenterol. 2004, 99: 2158- 65.
32. **Imber C. and Davidson B.** Hepatobiliary tumours. *Medicine* (2006), 35: 1- 4.
 33. **Bruix J, and Llovet J.M** Prognostic Prediction and Treatment Strategy in Hepatocellular Carcinoma. *Hepatology*, Vol. 35, 518-524, 2002.
 34. **Geller DA, Tsung A, Marsh JW, et al** Outcome of 1000 Liver Cancer Patients Evaluated at the UPMC Liver Cancer Center. *Journal of GastroIntestinal Surgery* 2006; Vol. 10, No. 1:63-68.
 35. **Sass DA. and Chopra KB.** Clinical Features and Diagnostic Evaluation of Hepatocellular Carcinoma. *Hepatocellular Cancer*, Carr, 2005.
 36. **Bosch FX, Ribes J, Cle'ries R. et al** Epidemiology of Hepatocellular Carcinoma. *Clin Liver Dis* 9 (2005) 191- 211.
 37. **Kojiro M.** Histopathology of liver cancers. *Best Practice & Research Clinical Gastroenterology*. Vol. 19(1), pp. 39-62, 2005.
 38. **Anthony P.** Liver Pathology for the Practicing Surgeon. *Surgery* (Oxford) 2003, pp 3- 6.
 39. **Orikasa H, Ohyama R, Tsuka N, Eyden Bp, Yamazaki k.** Lipid-rich clear-cell hepatocellular carcinoma arising in non-alcoholic steatohepatitis in a patient with diabetes mellitus *J Submicrosc Cytol Pathol* 2001;33:195-200.
 40. **Emile J, Lemoine A, Azoulay D, et al.** Histological, genomic and clinical heterogeneity of clear cell hepatocellular carcinoma. *Histopathology* 2001 ;38:225-231.
 41. **Okuda H.** Hepatocellular carcinoma development in cirrhosis *Best Practice & Research Clinical Gastroenterology*. Vol. 21, No.1. pp. 161-173, 2007.
 42. **Lauwers GY, Terris B, Balis UJ, et al** Prognostic histologic indication of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic prognostic index. *Am J Surg Pathol* 2002;26:25-34.
 43. **Standish R.A. and Davies S.E.** Bile duct tumours. *Current Diagnostic Pathology* (2002) 8, 160-171.
 44. **Slattery J.M, and Sahani D. V.** What Is the Current State-of the Art Imaging for Detection and staging of Cholangiocarcinoma? *Oncologist* 2006;238;549-559.
 45. **Khan S.A, Thomas B.C, Davidson B.R. et al.** Cholangiocarcinoma, samlaner *Lancet* 2005; 366: 1303-14 ... "
 46. **Singh P. and Patel T.** Advances in the diagnosis. Evaluation and management of cholangiocarcinoma. *Current Opinion in Gastroenterology* 2006, 22:294-299.
 47. **Kuroki Tajima Y. and Kanematsu T.** Hepatolithiasis and intrahepatic cholangiocarcinoma: carcinogenesis based on molecular mechanisms, *J Hepatobiliary Pancreat Surg.* 2005, 12:463- 466.
 48. **Broelsch C.E, Frilling A. and Malago M** Hepatoma; resection or transplantation. *Surg Clin N Am* 84 (2004) 495-511.
 49. **Malhi H, Gores G.J.** Cholangiocarcinoma: Modern advances in understanding

- a deadly old disease. *Journal of Hepatology* 45 (2006) 856-867.
50. **Leonga TY, Wannakrairoth P, Lee E.S. et al.** Pathology of cholangiocarcinoma. *Current Diagnostic Pathology* (2007) 13, 54-64.
 51. **Stocker JT.** Hepatic Tumors in Children. *Clinics in Liver Disease*. Vol. 5(1)2001.
 52. **Ross JA, Gurney Jc** : Hepatoblastoma incidence in the united states from 1973 to 1992 *med pediater oncol* 30: 141- 142,1998.
 53. **Lazaridis K.N, and Gores G.J.** Cholangiocarcinoma. *Gastroenterology* 2005; 128: 1655-1667.
 54. **O'Grady J.G.** Treatment Options for Other Hepatic Malignancies. *Liver Transplantation*, Vol 6, No 6, Suppl 2 (November), 2000: pp S23-S29.
 55. **Suriawinata A.A. and Thung S.N.** Malignant liver tumors. *Clin Liver Dis*. 2002, 6. 527- 554.
 56. **Anthony P.** Hepatocellular carcinoma: an overview. *Histopathology* 2001, 39, 109-118.
 57. **Sherlock S. and Dooley J.** Anatomy and Function. In: Sheila C. And J Dooley ,t eds. *Diseases of the Liver and Biliary System*. 11th Ed, Blackwell Science 2002: 1-17
 58. **DeMatteo RP. And Fong, Y.** Hepatic Resection for Colorectal Liver Metastases: Surgical Indications and Outcomes. In: *Hepatobiliary. Surgery* Chamberlain RS and Blumgart LH (eds) *Vademecum*. Landes Bioscience 2004; PP. 121-128.
 59. **Wang YX, Hussain SM, Krestin GP.** Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. *Eur Radiol* 2001; 11:2319-2331.
 60. **Bhattacharya S, Lobo FD, Pai PK, et al** Hepatic neoplasms in childhood – a clinicopathologic study. *Pediatr Surg Int* 1998; 14: 51-54.
 61. **Semelka RC, Cance WG, Marcos HB, et al.** Liver metastases: comparison of current MR techniques and spiral CT during arterial portography for detection in 20 surgically staged cases. *Radiology* 1999;213: 86– 91.
 62. **Braga L, Semelka RC, Pedro MS, et al.** Post-treatment malignant liver lesions. MR imaging. *Magn Reson Imaging Clin N Am* 2002; 10:53-73.
 63. **Van Hoe L, Mermuys K, Vanhoenacker P** (2004)MRCP pitfalls.*Abdom Imaging* 29 : 360–387.
 64. **Horowitz ME, Etcubanas E, Webber BL, Kun LE, Rao BN, Vogel RJ, Pratt CB.** Hepatic undifferentiated (embryonal) sarcoma and rhabdomyosarcoma in children. *Cancer* 1987; 59:396-402 Horowitz 1995.
 65. **Hashemi RH, Bradley WG (1997) MRI.** The basics. Williams & Wilkins, Baltimore
 66. **Westbrook C Kout C (1993) MRI in practice Blackwell scientific , Oxford .**
 67. **Bachir Taouli and Dow-mu ,** Diltusion weighted MR 2010 1-18.

68. **Hamm B, Wolf KJ, Felix R.** Conventional and rapid MR imaging of the liver with Gd-DTPA. *Radiology* 1987; 164:313-320.
69. **Reimer P, Schneider G, Schima W.** Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. *Eur Radiol* 2004; 14:559-578.
70. **Bellin MF, Vasile M, Morel-Precetti S.** Currently used non-specific extracellular MR contrast media. *Eur Radiol* 2003; 13:2688-2698.
71. **Tweedle MF, Wedeking P, Krishan K.** Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. *Invest Radiol* 1995; 30:372-380.
72. **Karabulut N, Elmas N.** *Diagnostic Interventional Radiology* 2006; 12:22-30 Turkish society of radiology 2006.
73. **Semelka et al, 2001 Semelka RC, Helmberger TK.** Contrast agents for MR imaging of the liver. *Radiology* 2001;218:27– 38.
74. **Mathieu D, Coffin C, Kobeiter H, Caseiro- Alves F, Mahfouz A, Rahmouni A, Diche T.** Unexpected MR-T1 enhancement of endocrine liver metastases with mangafodipir. *J Magn Reson Imaging* 1999; 10:193-195.
75. **Marti-Bonmati L, Fog AF, de Beeck BO, Kane P, Fagertun H.** Safety and efficacy of mangafodipir trisodium in patients with liver lesions and cirrhosis. *Eur Radiol* 2003; 13:1685-1692.
76. **Federle et al, 2000 12. Federle M, Chezmar J, Rubin DL, et al.** Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: results of the U. S. multicenter phase III clinical trials. Efficacy of early imaging. *J Magn Reson Imaging* 2000; 12:689-701. Ferrell et al, 1992).
77. **Precetti-Morel S, Bellin MF, Ghebontni L, et al.** Focal nodular hyperplasia of the liver on ferumoxides-enhanced MR imaging: features on conventional spin-echo, fast spin-echo and gradient-echo pulse sequences. *Eur Radiol* 1999; 9:1535-1542.
78. **Huppertz A, Balzer T, Blakeborough A, et al.** Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. *Radiology* 2004; 230:266-275.
79. **Kim MJ, Kim JH, Chung JJ, et al.** Focal hepatic lesions: detection and characterization with combination gadolinium- and superparamagnetic iron oxide-enhanced MR imaging. *Radiology* 2003; 228:719- 726.
80. **Siewert B, Muller MF, Foley M, et al.** Fast MR imaging of the liver: quantitative comparison of techniques. *Radiology* 1994;193:37-42
81. **Kim YK, Kim CS, Kwak HS, Lee JM.** Threedimensional dynamic liver MR imaging using sensitivity encoding for detection of hepatocellular carcinomas: comparison with superparamagnetic iron oxide enhanced MR imaging. *J Magn Reson Imaging* 2004; 20:826-837.
82. **Rofsky NM, Lee VS, Laub G, et al.** Abdominal MR imaging with a volumetric interpolated breathhold examination. *Radiology* 1999;212:876-884

83. **Sodickson DK, McKenzie CA.** A generalized approach to parallel magnetic
84. **Schneider G, Grazioli L and Saini S .** MRI of the liver imaging Techniques, Contrast Enhancement, Differential Diagnosis. Radiology 2006.
85. **Imam K, Bluemke DA.** MR imaging in the evaluation of hepatic metastases. Magn Reson Imaging Clin N Am 2000;8(4):741-56.
86. **Tropp J.** Image brightening in samples of high dielectric constant. J Magn Reson 2004;167:12-24.
87. **Brix B, Seebass M, Hellwig G, Griebel J.** Estimation of heat transfer and temperature rise in partialbody regions during MR procedures: an analytical approach with respect to safety considerations. Magn Reson Imaging 2002; 20:65-76.
88. **Robinson P, Ward J.** MRI of the liver A practical guide 2006;6,111-123.
89. **Grazioli L, Morana G, Kirchin MA, et al.** Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 2005;236:166-177
90. **Molina EG, Schiff ER.** Benign solid lesions of the liver. In: Schiff's: Diseases of the liver. (8th ed), Vol. II. Lippincott-Raven 1999,1254-1257
91. **Grazioli L, Morana G, Federle MP, et al.** Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine. Radiology 2001;221:731-739
92. **Verhaegen F, Poey C, Lebras Y, et al.** X-ray computed tomographic tests in the diagnosis and treatment of amebic liver abscesses. J Radiol 1996;77:23-28.
93. **Balci NC, Semelka RC, Noone TC, et al.** Pyogenic hepatic abscess: MR findings on T1- and T2- weighted and serial Gadolinium-enhanced gradient-echo images. J Magn Reson Imaging 1999; 9:285-290
94. **Arrive L, Flejou JF, Vilgrain V, et al.** Hepatic adenoma: MR findings in 51 pathologically proved lesions. Radiology 1994; 193: 507-512
95. **Schima W, Saini S, Echeverri JA, et al.** Focal liver lesions: characterization with conventional spinecho versus fast spin-echo T2-weighted MR imaging. Radiology 1997;202:389-393
96. **McFarland EG, Mayo-Smith WW, Saini S, et al.** Hepatic hemangiomas and malignant tumors: improved differentiation with heavily T2-weighted conventional spin-echo MR imaging. Radiology 1994;193:43-47
97. **Saini S, Edelman RR, Sharma P, Li W, Mayo- Smith W, Slater GJ, Eisenberg PJ, Hahn PF.** Blood-pool MR contrast agent material for detection and characterization of focal hepatic lesions. Initial clinical experience with superparamagnetic iron oxide (AMI-227). Am J Roentgenol 1995; 164:1447-1152
98. **Imai Y, Murakami T, Yoshida S, et al.** Superparamagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading. Hepatology 2000; 32: 205- 212

99. **Lim J H, Cho JM, Kim EY, et al.** Dysplastic nodules in liver cirrhosis: evaluation of homodynamic with CT during arterial portography and CT hepatic arteriography. *Radiology* 2000; 214: 869-874
100. **Grazioli, L, Federle, MP, Brancatelli, G, et al.** Hepatic adenomas: Imaging and pathologic findings. *Radiographics* 2001; 21:877.
101. **Grazioli L, Federle MP, Ichikawa T, et al.** Liver adenomatosis: clinical, histopathologic and imaging findings in 15 patients. *Radiology* 2000;216:395-402
102. **Stevens WR, Gulino SP, Batts KP, et al.** Mosaic pattern of hepatocellular carcinoma: histologic basis for a characteristic CT appearance. *J Comput Assist Tomogr* 1996; 20:337-342
103. **Krinsky GA, Lee VS, Theise ND, et al.** Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: prospective diagnosis with MR imaging and explanation correlation. *Radiology* 2001;219:445-454
104. **Tang Y, Yamashita Y, Arakawa A, Namimoto T, Mitsuzaki K, Abe Y, Katahira K, Takahashi M.** Detection of hepatocellular carcinoma arising in cirrhotic livers : comparison of gadolinium- and ferumoxides-enhanced MR imaging. *Am J Roentgenol* 1999; 172:1547-1554.
105. **Murakami T, Kim T, Takamura M, et al.** Hepatitis, cirrhosis and hepatoma. *J Magn Reson Imaging* 1998;8:346-358
106. **Senéterre E, Taourel P, Bouvier Y, et al.** Detection of hepatic metastases: Ferumoxides-enhanced MR Imaging versus unenhanced MR Imaging and CT during arterial portography. *Radiology* 1996; 200: 785-792
107. **Coffin CM, Diche T, Mahfouz A, et al.** Benign and malignant hepatocellular tumors: Evaluation of tumoral enhancement after mangafodipir trisodium injection on MR imaging. *Eur Radiol* 1999; 9: 444- 449
108. **Goodman ZD.** Nonparenchymal and metastatic malignant tumors of the liver. In: Haubrich WS, Schaffner F, Berk JE (eds): *Bockus Gastroenterology*. Philadelphia: WB Saunders, 1995;2488-2500
109. **Worawattanakul S, Semelka RC, Noone TC, et al.** Cholangiocarcinoma: spectrum of appearances on MR images using current techniques. *Magn Reson Imaging* 1998; 16: 993-1003.
110. **Caudana R, Morana G, Pirovano GP, Nicoli N, Portuese A, Spinazzi A, Di Rito R, Pistolesi GF.** Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA) - preliminary results of phase II clinical application. *Radiology* 1996; 199:513-520
111. **Yoshida Y, Imai Y, Murakami T, et al.** Intrahepatic cholangiocarcinoma with marked hypervascularity. *Abdom Imaging* 1999; 24: 66-68.
112. **Lacomis JM, Baron RL, Oliver JH, Federle MP, Nalesnik M.** Cholangiocarcinoma: Delayed CT contrast enhancement patterns. *Radiology* 1997;203:98- 104

1. **Samantha Kubaska , Dushyan TV , Sahan I , Sanjay Saint Peter . Hahn Elkan Haipern (2001)** : Dual Contrast Enhanced magnetic Resonance Imaging of the liver with super paramagnetic Iron Oxide Followed by gadolinium for Lesion Detection and characterization .56: 410 – 415 .
2. **L. J. King , G . J .C Burkill , E . D Scurr , P.Vavianos, I.Murray. Lyons , J .C Healy(2002)** : MNDPDP enhanced Magnetic Resonance Imaging of Focal liver lesion clinical radiology 57:1047 – 1057 .
3. **Word J , Naik Ks , Guthrie JA , Wilson D and Robinson PJ (1999)** : Hepatic lesion detection : comparison of MR imaging after the administration of super paramagnetic iron oxide with dual phase CT by using alternative . free response receiver operating characteristic analysis , Radiology , 210 (2) : 459- 66.
4. **Soyer p Gueye C , Somveille e , et al . (1995)** : MR diagnosis of hepatic metastasis form neuroendocrine tumors versus haemangiomas : Relative merits of dynamic gadolinium chelate-enhanced gradient recalled echo and unenhanced spin echoimages . A.JR Am J Roentgenol 165 : 1407
5. **Vilgerian V , silbermann O , Benhamou J.P , et al (1993):** MR imaging in intracystic haemorrhage of simple hepatic cysts , Abdomen imaging 18:164 .
6. **Semelka RC, Khoenot OP, Kroeker MA et al . (1992)** : Focal liver disease Comparison of dynamic contrast enhanced CT and T2 weighted Fat suppressed , Flash , and dynamic gadolinium - enhanced MR imaging at 1.5 T. Radiology . 184 , 687- 694 .
7. **Parks.R-W- and oniscu G.G.** Benign Condition of the liver – surgrey 2006, 25 (1) 22 – 27 .
8. **Gibbs J.F, Litwin A.M, and Kahlenberg M.S.** Contemporary management of benign liver tumors. Surg Clin N Am 84 (2004) 463-480.
9. **Prabhu V.R, and Burt D.A.** Pathology of liver tumors, Surgery (2006), 1- 6.
10. **Crawford J.M.** Liver and Biliary Tract. In: Robbins and Cotran eds. Pathologic Basis of Disease, 7th ed., Kumar V, Abbas A and Fausto N. eds. Saunders 2005: 877- 939
11. **Kakar S, and Burgart L.J.** Tumours of the biliary system. Current Diagnostic Pathology (2005) 11,34-43.
12. **Anthony PP.** Tumors and tumor-like lesions of the liver and biliary tract: etiology, epidemiology and pathology. In: RNM MacSween, AD Burt, BC Portmann, et al ed. Pathology of the Liver. 4th Ed. Churchill, Livingstone 2002: 711-776.
13. **John G.C., Sergio H., Hohn A.B.** Hepatobiliary cystadenoma: A case report and a review of the Literature, Current Surgery Vol. 63(4), 2006: 286-289.
14. **Linehan DC, Jarnagin WR. and Blumgart LH.** Benign Tumors and Pseudotumors of the biliary tract. In: Surgery of the liver, Biliary Tract and Pancreas 4th ed. Blumgart LH (ed). Philadelphia saunders 2007; pp. 802-828.

15. **Saegusa, T, Ito, K, Oba, N, et al**, Enlargement of multiple cavernous hemangioma of the liver in association with pregnancy , Intern Med 1995;34;207.
16. **Winkfield, B, Vuillemin, E, Rousselet, MC, et al** Progression of a hepatic hemangioma under progestins. Gastroenterol Clin Biol 2001; 25: 108.
17. **Farges O, Daradkeh S, Bismuth H**. Cavernous hemangiomas of the liver: Are there any indications for resection? World J Surg 1995; 19:19.
18. **Toshikuni, N, Kawaguchi, K, Miki, H, et al**. Focal nodular hyperplasia coexistent with hemangioma and multiple cysts of the liver. J Gastroenterol 2001; 36:206.
19. **Moon, WS, Yu, HC, Lee, JM, Kang, MJ**. Diffuse hepatic hemangiomatosis in an adult. J Korean Med Sci 2000; 15:471.
20. **Lehmann, FS, Beglinger, C, Schnabel, K, et al** , progressive development of diffuse liver hemangiomatosis. J Hepatol 1999; 30:951.
21. **Haitjema, T, Westermann, CJ, Overtom, TT, et al**. Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease): New insights in pathogenesis, complications, and treatment, Arch Intern Med 1996; 156:714.
22. **Glinkova, V, Shevah, O, Boaz, M, et al**. Hepatic haemangiomas: possible association with female sex hormones. Gut 2004; 53:1352.
23. **Chamberlain R.S**. Benign liver tumors. In: Hepatobiliary Surgery. Chamberlain RS and Blumgart LH (eds) Vademecum. Landes Bioscience 2004; PP. 80-100.
25. **Selby DM, Stocker JT, Waclawiw Ma et al**, Infantile Hemangioendothelioma of the liver , Hepatology 1994;20;39-45 .
26. **Nazir Z, and Pervez S**. Malignant vascular tumors of liver in neonates, Journal of Pediatric Surgery (2006) 41, E49-E51.
27. **Klein WM, Molmenti EP, Colombani PM, et al** Primary Liver Carcinoma Arising in People Younger Than 30 Years. Am J Clin Pathol 2005; 124:512-518.
28. **Levy A.D**. Hepatic Imaging And Intervention. Clinics in Liver Disease 2002, Vol. 6,1:147-162.
29. **Heimberger JR, Ros PR, Medgo PJ, et al** Pediatric liver neoplasms: a radiology - pathological correlation. Eur Radiol 1999; 9: 1339-1347.
30. **Belghiti j, Vilgrain V, and Paradis V**. Benign Liver Tumors. In: Surgery of the Liver, Biliary Tract and Pancreas 4th ed. Blumgart LH (ed) Philadelphia Saunders, 2007; pp. 1131-1151
31. **Wilson J.F**. Liver Cancer on the Rise. Annals of Internal Medicine 2005; 142, 12: 1029- 1032
32. **Lang B.H., Poon R.T., Fan S.T. and Wong J**. Outcomes of patients with hepatocellular carcinoma presenting with variceal bleeding, Am. J Gastroenterol. 2004, 99: 2158- 65.
33. **Imber C. and Davidson B**. Hepatobiliary tumours. Medicine (2006), 35: 1- 4.
34. **Bruix J, and Llovet J.M** Prognostic Prediction and Treatment Strategy in Hepatocellular Carcinoma. Hepatology, Vol. 35, 518-524, 2002.

35. **Geller DA, Tsung A, Marsh JW, et al** Outcome of 1000 Liver Cancer Patients Evaluated at the UPMC Liver Cancer Center. *Journal of Gastrointestinal Surgery* 2006; Vol. 10, No. 1:63-68.
36. **Sass DA. and Chopra KB.** Clinical Features and Diagnostic Evaluation of Hepatocellular Carcinoma. *Hepatocellular Cancer*, Carr, 2005.
37. **Bosch FX, Ribes J, Cle'ries R. et al** Epidemiology of Hepatocellular Carcinoma. *Clin Liver Dis* 9 (2005) 191- 211.
38. **Kojiro M.** Histopathology of liver cancers. *Best Practice & Research Clinical Gastroenterology*. Vol. 19(1), pp. 39-62, 2005.
39. **Anthony P.** *Liver Pathology for the Practicing Surgeon*. Surgery (Oxford) 2003, pp 3- 6.
40. **Orikasa H, Ohyama R, Tsuka N, Eyden Bp, Yamazaki k.** Lipid-rich clear-cell hepatocellular carcinoma arising in non-alcoholic steatohepatitis in a patient with diabetes mellitus *J Submicrosc Cytol Pathol* 2001;33:195-200.
41. **Emile J, Lemoine A, Azoulay D, et al.** Histological, genomic and clinical heterogeneity of clear cell hepatocellular carcinoma. *Histopathology* 2001 ;38:225-231.
42. **Okuda H.** Hepatocellular carcinoma development in cirrhosis *Best Practice & Research Clinical Gastroenterology*. Vol. 21, No.1. pp. 161e173, 2007.
43. **Lauwers GY, Terris B, Balis UJ, et al** Prognostic histologic indicators of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic prognostic index. *Am J Surg Pathol* 2002;26:25-34.
44. **Standish R.A. and Davies S.E.** Bile duct tumours. *Current Diagnostic Pathology* (2002) 8, 160-171.
45. **Slattery J.M, and Sahani D. V.** What Is the Current State-of the Art Imaging for Detection and staging of Cholangiocarcinoma? *Oncologist* 2006;238;549-559.
46. **Khan S.A, Thomas B.C, Davidson B.R. et al.** Cholangiocarcinoma, samlaner *Lancet* 2005; 366: 1303-14 ... "
47. **Singh P. and Patel T.** Advances in the diagnosis. Evaluation and management of cholangiocarcinoma. *Current Opinion in Gastroenterology* 2006, 22:294-299.
48. **Kuroki Tajima Y. and Kanematsu T.** Hepatolithiasis and intrahepatic cholangiocarcinoma: carcinogenesis based on molecular mechanisms, *J Hepatobiliary Pancreat Surg*. 2005, 12:463- 466.
49. **Broelsch C.E, Frilling A. and Malago M** Hepatoma; resection or transplantation. *Surg Clin N Am* 84 (2004) 495-511.
50. **Malhi H, Gores G.J.** Cholangiocarcinoma: Modern advances in understanding a deadly old disease. *Journal of Hepatology* 45 (2006) 856-867.
51. **Leonga TY, Wannakrairoth P, Lee E.S. et al.** Pathology of cholangiocarcinoma. *Current Diagnostic Pathology* (2007) 13, 54-64.
52. **Stocker JT.** Hepatic Tumors in Children. *Clinics in Liver Disease*. Vol. 5(1)2001.

53. **Ross JA, Gurney Jc** : Hepatoblastoma incidence in the united states from 1973 to 1992 med pediater oncol 30: 141- 142,1998.
54. **Lazaridis K.N, and Gores G.J.** Cholangiocarcinoma. Gastroenterology 2005; 128: 1655-1667.
55. **O'Grady J.G.** Treatment Options for Other Hepatic Malignancies. Liver Transplantation, Vol 6, No 6, Suppl 2 (November), 2000: pp S23-S29.
56. **Suriawinata A.A. and Thung S.N.** Malignant liver tumors. Clin Liver Dis. 2002, 6. 527- 554.
57. **Anthony P.** Hepatocellular carcinoma: an overview. Histopathology 2001, 39, 109-118.
58. **Sherlock S. and Dooley J.** Anatomy and Function. In: Sheila C. And J Dooley ,t eds. Diseases of the Liver and Biliary System. 11th Ed, Blackwell Science 2002: 1-17
59. **DeMatteo RP. And Fong, Y.** Hepatic Resection for Colorectal Liver Metastases: Surgical Indications and Outcomes. In: Hepatobiliary. Surgery Chamberlain RS and Blumgart LH (eds) Vademecum. Landes Bioscience 2004; PP. 121-128.
60. **Wang YX, Hussain SM, Krestin GP.** Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol 2001; 11:2319-2331.
61. **Bhattacharya S, Lobo FD, Pai PK, et al** Hepatic neoplasms in childhood – a clinicopathologic study. Pediatr Surg Int 1998: 14: 51-54.
62. **Semelka RC, Cance WG, Marcos HB, et al.** Liver metastases: comparison of current MR techniques and spiral CT during arterial portography for detection in 20 surgically staged cases. Radiology 1999;213: 86– 91.
63. **Braga L, Semelka RC, Pedro MS, et al.** Post-treatment malignant liver lesions. MR imaging. Magn Reson Imaging Clin N Am 2002; 10:53-73.
64. **Van Hoe L, Mermuys K, Vanhoenacker P** (2004)MRCP pitfalls.Abdom Imaging 29 : 360–387.
65. **Horowitz ME, Etcubanas E, Webber BL, Kun LE, Rao BN, Vogel RJ, Pratt CB.** Hepatic undifferentiated (embryonal) sarcoma and rhabdomyosarcoma in children. Cancer 1987; 59:396-402 Horowitz 1995.
66. **Hashemi RH, Bradley WG (1997) MRI.** The basics. Williams & Wilkins, Baltimore
68. **Westbrook C Kout C (1993) MRI in practice Blackwell scientific , Oxford .**
69. **Bachir Taouli and Dow-mu ,** Diltusion weighted MR 2010 1-18.
70. **Hamm B, Wolf KJ, Felix R.** Conventional and rapid MR imaging of the liver with Gd-DTPA. Radiology 1987; 164:313-320.
71. **Reimer P, Schneider G, Schima W.** Hepatobiliary contrast agents for contrastenhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 2004; 14:559-578.

72. **Bellin MF, Vasile M, Morel-Precetti S.** Currently used non-specific extracellular MR contrast media. *Eur Radiol* 2003; 13:2688-2698.
73. **Tweedle MF, Wedeking P, Krishan K.** Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. *Invest Radiol* 1995; 30:372-380.
74. **Karabulut N, Elmas N.** Diagnostic Interventional Radiology 2006; 12;22-30 Turkish society of radiology 2006.
75. **Semelka et al, 2001 Semelka RC, Helmberger TK.** Contrast agents for MR imaging of the liver. *Radiology* 2001;218:27– 38.
76. **Mathieu D, Coffin C, Kobeiter H, Caseiro- Alves F, Mahfouz A, Rahmouni A, Diche T.** Unexpected MR-T1 enhancement of endocrine liver metastases with mangafodipir. *J Magn Reson Imaging* 1999; 10:193-195.
77. **Marti-Bonmati L, Fog AF, de Beeck BO, Kane P, Fagertun H.** Safety and efficacy of mangafodipir trisodium in patients with liver lesions and cirrhosis. *Eur Radiol* 2003; 13:1685-1692.
78. **Federle et al, 2000 12. Federle M, Chezmar J, Rubin DL, et al.** Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: results of the U. S. multicenter phase III clinical trials. Efficacy of early imaging. *J Magn Reson Imaging* 2000; 12:689-701. Ferrell et al, 1992).
79. **Precetti-Morel S, Bellin MF, Ghebontni L, et al.** Focal nodular hyperplasia of the liver on ferumoxides-enhanced MR imaging: features on conventional spin-echo, fast spin-echo and gradient-echo pulse sequences. *Eur Radiol* 1999; 9:1535-1542.
80. **Huppertz A, Balzer T, Blakeborough A, et al.** Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid- enhanced MR images with intraoperative findings. *Radiology* 2004; 230:266-275.
81. **Kim MJ, Kim JH, Chung JJ, et al.** Focal hepatic lesions: detection and characterization with combination gadolinium- and superparamagnetic iron oxide-enhanced MR imaging. *Radiology* 2003; 228:719- 726.
83. **Siewert B, Muller MF, Foley M, et al.** Fast MR imaging of the liver: quantitative comparison of techniques. *Radiology* 1994;193:37-42
84. **Kim YK, Kim CS, Kwak HS, Lee JM.** Threedimensional dynamic liver MR imaging using sensitivity encoding for detection of hepatocellular carcinomas: comparison with superparamagnetic iron oxide enhanced MR imaging. *J Magn Reson Imaging* 2004; 20:826-837.
85. **Rofsky NM, Lee VS, Laub G, et al.** Abdominal MR imaging with a volumetric interpolated breathhold examination. *Radiology* 1999;212:876-884
86. **Sodickson DK, McKenzie CA.** A generalized approach to parallel magnetic
87. **Schneider G, Grazioli L and Saini S .** MRI of the liver imaging Techniques, Contrast Enhancement, Differential Diagnosis. *Radiology* 2006.
88. **Imam K, Bluemke DA.** MR imaging in the evaluation of hepatic metastases. *Magn Reson Imaging Clin N Am* 2000;8(4):741-56.

89. **Tropp J.** Image brightening in samples of high dielectric constant. *J Magn Reson* 2004;167:12-24.
90. **Brix B, Seebass M, Hellwig G, Griebel J.** Estimation of heat transfer and temperature rise in partialbody regions during MR procedures: an analytical approach with respect to safety considerations. *Magn Reson Imaging* 2002; 20:65-76.
91. **Robinson P, Ward J.** MRI of the liver A practical guide 2006;6,111-123.
92. **Grazioli L, Morana G, Kirchin MA, et al.** Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. *Radiology* 2005;236:166-177
93. **Molina EG, Schiff ER.** Benign solid lesions of the liver. In: Schiff's: Diseases of the liver. (8th ed), Vol. II. Lippincott-Raven 1999,1254-1257
94. **Grazioli L, Morana G, Federle MP, et al.** Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine. *Radiology* 2001;221:731-739
95. **Verhaegen F, Poey C, Lebras Y, et al.** X-ray computed tomographic tests in the diagnosis and treatment of amebic liver abscesses. *J Radiol* 1996;77:23-28.
96. **Balci NC, Semelka RC, Noone TC, et al.** Pyogenic hepatic abscess: MR findings on T1- and T2- weighted and serial Gadolinium-enhanced gradient- echo images. *J Magn Reson Imaging* 1999; 9:285-290
97. **Arrive L, Flejou JF, Vilgrain V, et al.** Hepatic adenoma: MR findings in 51 pathologically proved lesions. *Radiology* 1994; 193: 507-512
98. **Schima W, Saini S, Echeverri JA, et al.** Focal liver lesions: characterization with conventional spinecho versus fast spin-echo T2-weighted MR imaging. *Radiology* 1997;202:389-393
99. **McFarland EG, Mayo-Smith WW, Saini S, et al.** Hepatic hemangiomas and malignant tumors: improved differentiation with heavily T2-weighted conventional spin-echo MR imaging. *Radiology* 1994;193:43-47
101. **Saini S, Edelman RR, Sharma P, Li W, Mayo-Smith W, Slater GJ, Eisenberg PJ, Hahn PF.** Blood-pool MR contrast agent material for detection and characterization of focal hepatic lesions. Initial clinical experience with superparamagnetic iron oxide (AMI-227). *Am J Roentgenol* 1995; 164:1447-1152
102. **Imai Y, Murakami T, Yoshida S, et al.** Superparamagneticiron oxide-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading. *Hepatology* 2000; 32: 205- 212
103. **Lim J H, Cho JM, Kim EY, et al.** Dysplastic nodules in liver cirrhosis: evaluation of homodynamic with CT during arterial portography and CT hepatic arteriography. *Radiology* 2000; 214: 869-874
104. **Grazioli, L, Federle, MP, Brancatelli, G, et al** Hepatic adenomas: Imaging and pathologic findings. *Radiographics* 2001; 21:877.

105. **Grazioli L, Federle MP, Ichikawa T, et al.** Liver adenomatosis: clinical, histopathologic and imaging findings in 15 patients. *Radiology* 2000;216:395-402
106. **Stevens WR, Gulino SP, Batts KP, et al.** Mosaic pattern of hepatocellular carcinoma: histologic basis for a characteristic CT appearance. *J Comput Assist Tomogr* 1996; 20:337-342
107. **Krinsky GA, Lee VS, Theise ND, et al.** Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: prospective diagnosis with MR imaging and explanation correlation. *Radiology* 2001;219:445-454
108. **Tang Y, Yamashita Y, Arakawa A, Namimoto T, Mitsuzaki K, Abe Y, Katahira K, Takahashi M.** Detection of hepatocellular carcinoma arising in cirrhotic livers : comparison of gadolinium- and ferumoxides-enhanced MR imaging. *Am J Roentgenol* 1999; 172:1547-1554.
109. **Murakami T, Kim T, Takamura M, et al.** Hepatitis, cirrhosis and hepatoma. *J Magn Reson Imaging* 1998;8:346-358
110. **Sen  terre E, Taourel P, Bouvier Y, et al.** Detection of hepatic metastases: Ferumoxides-enhanced MR Imaging versus unenhanced MR Imaging and CT during arterial portography. *Radiology* 1996; 200: 785-792
111. **Coffin CM, Diche T, Mahfouz A, et al.** Benign and malignant hepatocellular tumors: Evaluation of tumoral enhancement after mangafodipir trisodium injection on MR imaging. *Eur Radiol* 1999; 9: 444- 449
112. **Goodman ZD.** Nonparenchymal and metastatic malignant tumors of the liver. In: Haubrich WS, Schaffner F, Berk JE (eds): *Bockus Gastroenterology*. Philadelphia: WB Saunders, 1995;2488-2500
113. **Worawattanakul S, Semelka RC, Noone TC, et al.** Cholangiocarcinoma: spectrum of appearances on MR images using current techniques. *Magn Reson Imaging* 1998; 16: 993-1003.
114. **Caudana R, Morana G, Pirovano GP, Nicoli N, Portuese A, Spinazzi A, Di Rito R, Pistolesi GF.** Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA) - preliminary results of phase II clinical application. *Radiology* 1996; 199:513-520
115. **Yoshida Y, Imai Y, Murakami T, et al.** Intrahepatic cholangiocarcinoma with marked hypervascularity. *Abdom Imaging* 1999; 24: 66-68.
116. **Lacomis JM, Baron RL, Oliver JH, Federle MP, Nalesnik M.** Cholangiocarcinoma: Delayed CT contrast enhancement patterns. *Radiology* 1997;203:98- 104